Online Program

291037
Insecticide treated wall liner: Cost-effectiveness of a new tool for malaria prevention


Tuesday, November 5, 2013 : 10:45 a.m. - 11:00 a.m.

Donald S. Shepard, PhD, The Heller School for Social Policy and Management, Brandeis University, Waltham, MA
Elizabeth Glaser, PhD, MSc, ACRN, Heller School for Social Policy and Management, Brandeis University, Institute for Global Health and Development, Waltham, MA
George Olang, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
Nabie Bayoh, PhD, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
Frank Odhiambo, PhD, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
Vincent Were, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
Peter Otieno, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya
Simon Kariuki, PhD, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI), Kenya
Meghna Desai, PhD, Centre for Global Health Research, KEMRI/CDC, Kenya Medical Research Institute (KEMRI)/US Centers for Disease Control, Kisumu, Kenya
John Gimnig, PhD, Malaria Branch, Division of Parasitic Diseases, US Centers for Disease Control, Atlanta, Atlanta, GA
Mary Hamel, MD, USAID Global Health Bureau; Medical epidemiologist, Malaria Branch, CDC., Centers for Disease Control and Prevention, Washington, DC
Aggrey Kihombo, PhD, Mzumbe University, Mzumbe, Tanzania
Angelique Rwiyereka, MBBS, MA, MS, Heller School for Social Policy and Management, Brandeis University, Waltham, MA
While insecticide treated nets (ITNs) and other strategies have reduced the burden of malaria, the disease remains a major cause of morbidity and mortality across sub-Saharan Africa. We assessed the cost-effectiveness of a promising new malaria prevention tool, the insecticide treated wall liner (ITWL). Its manufacturer projects a useful life of 3-4 years. The efficacy of ITWL is based on a 6-month cluster randomized trial by Gimnig et al of 1,592 children (aged 6 months-11 years) in 12 rural villages in Nyanza Province, Kenya during 2010. Control villages had only ITNs; experimental villages had both ITNs and ITWLs. The cost-effectiveness analysis considered unit costs and quantities of each input, demographic records, and published literature. The adjusted protective efficacy for ITWL was 38% (95% CI: 23%-50%), or 1.1 infection averted per child per year. The added cost of ITWL was US$64.23 per person covered, consisting of ITWL's projected factory price (44.9%), shipping and offloading (5.1%), management and supervisory personnel (24.5%), installation materials (0.4%), local transportation (13.9%), and installation labor (11.1%). Under the least favorable assumption (ITWL protection ends at 3 months, the average follow up in the previous trial), the cost per discounted life-year gained (DLYG) is US$4,837. Under the most favorable assumption (ITWL remains effective for 4 years), the cost per DLYG is US$482. Kenya's per capita GDP in 2010 was US$795. WHO considers interventions with cost-effectiveness ratios below a country's GDP highly cost-effective. As long as ITWL remains effective for at least 2.2 years, it will be highly cost-effective.

Learning Areas:

Biostatistics, economics
Public health or related research

Learning Objectives:
Evaluate the cost-effectiveness of a new tool for malaria prevention Discuss key factors affecting the results.

Keyword(s): Cost-Effectiveness, Prevention

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Doanld Shepard is the Principal Investigator of a study on this topic sponsored by the Gates Foundation. Elizabeth Glaser is the Project Manager on this study.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.